BRISBANE, Calif., March 16, 2012 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, announced today that it will introduce the truSculpt™ body contouring system on March 17th at the 70th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego.
The truSculpt system provides non-invasive radio frequency treatment for body sculpting. Cutera's proprietary technology enables large volumetric deep tissue treatment with minimal discomfort and no downtime. The system features real-time temperature monitoring, and the ability to achieve predictable therapeutic temperatures in subcutaneous fat while maintaining comfortable levels in the skin.
Kevin Connors, president and CEO of Cutera, said, "We are very excited to enter the fast growing non-invasive body contouring market and introduce our truSculpt system to the dermatology community this upcoming weekend. With our extensive research and progress on energy delivery with this technology, we are able to consistently achieve efficacious clinical outcomes, while maintaining patient comfort. We expect to commence commercial shipments in mid 2012."
The truSculpt system has received CE Mark clearance for body contouring, body sculpting, fat reduction, and cellulite. In addition, it also has received FDA 510(K) clearance for deep tissue heating and the temporary improvement in the appearance of cellulite.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995: Specifically, statements concerning the features, effectiveness, treatable conditions, timing of commercial sales, and the potential market size for Cutera's new product, are forward-looking statements within the meaning of the Safe Harbor. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements and those other factors described in the section entitled, "Risk Factors", in Cutera's most recent Form 10-K as filed with the Securities and Exchange Commission on March 15, 2012. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.